---
schema_version: "secwatch.filing_event.v1"
accession: "0000064803-26-000097"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2026-08-05T10:32:06+00:00"
generated_at: "2026-08-05T10:35:34.466948+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVS Health Q2 2026 GAAP EPS $2.31, adj EPS $2.58; raises FY guidance to $7.90-$8.10 adj EPS

## Summary
- Total revenues $106.1B, up 7.3% YoY; GAAP diluted EPS $2.31 vs $0.80 prior year.
- Adjusted EPS $2.58 vs $1.81 prior year; Health Care Benefits MBR improved to 87.4% from 89.9%.
- Full-year 2026 guidance raised: GAAP EPS $6.84-$7.04 (from $6.24-$6.44), adj EPS $7.90-$8.10 (from $7.30-$7.50).
- Cash flow from operations guidance raised to at least $11.5B from at least $9.5B; YTD cash flow $10.6B.
- Health Services segment revenue up 11.5% to $51.8B; Pharmacy & Consumer Wellness prescriptions filled up 4.3%.

## SEC filing metadata
- accession: 0000064803-26-000097
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2026-08-05T10:32:06+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000006480326000097/0000064803-26-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000006480326000097/cvs-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000064803-26-000097
- JSON: https://secwatch.observer/filing/0000064803-26-000097.json
- Plain text: https://secwatch.observer/filing/0000064803-26-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.